Comparative Pharmacology
Head-to-head clinical analysis: AFIRMELLE versus KIMIDESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFIRMELLE versus KIMIDESS.
AFIRMELLE vs KIMIDESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive